Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

Sandoz (SDZNY) said that the European Commission has granted marketing authorization for Afqlir (aflibercept) 2 mg vial kit and ...

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

In this note, we will discuss the latest decisions on the merits from the Dutch patent court on the matter of plausibility and inventive step.

Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled syringe ...

The two-day event will see industry experts from across the clinical trial space holding talks on subjects from AI to ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

LVMH plans to ramp up manufacturing at its Zenith brand to supply movements for timepieces across the luxury group’s watch ...

Swiss stocks tumbled on Friday, weighed down data showing a slowdown in growth, and uncertainty about Fed interest rate cuts ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...